Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized Phase II Open Label Study to Assess the Efficacy & Safety of Gemcitabine + Abraxane With or Without ODSH (2-0, 3-0 Desulfated Heparin) as First Line Treatment of Metastatic Pancreatic Cancer

Next Previous
X
Search
Trial Profile

A Randomized Phase II Open Label Study to Assess the Efficacy & Safety of Gemcitabine + Abraxane With or Without ODSH (2-0, 3-0 Desulfated Heparin) as First Line Treatment of Metastatic Pancreatic Cancer

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 07 Jun 2022

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dociparstat sodium (Primary) ; Gemcitabine; Paclitaxel
  • Indications Pancreatic cancer
  • Focus Therapeutic Use
  • Acronyms PGPC1
  • Sponsors Chimerix

    • Most Recent Events

    • 31 May 2022 Status changed from completed to discontinued.
    • 24 Aug 2016 Status changed from recruiting to completed.
    • 26 Jan 2013 Interim results from the initial run in-phase (n=10) presented at the 2013 Gastrointestinal Cancers Symposium.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top